Status:
COMPLETED
Spread and Course of COVID-19 Infections
Lead Sponsor:
Goldhahn Jörg
Conditions:
Covid-19
Virus Disease
Eligibility:
All Genders
18-64 years
Brief Summary
The overall goal is to study the immune response to SARS-CoV-2 infection over the period of one year in the blood of a representative cohort of ETH students/employees.
Eligibility Criteria
Inclusion
- ETH employee or ETH student and their family members living in the same household at the start of the study
- Between 18 and 64 years of age at the start of the study
- Signed informed consent
Exclusion
- Age over 64 years at the start of the study
- In quarantine or self-confinement at the start of the study
- Active COVID-19 infection at the start of the study:
- Diagnosed with a laboratory test
- Suspected based on typical symptoms such as fever (\>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste
- The following medical condition
- With continuous steroid therapy/ chemotherapy/immunsuppressive therapy
- In treatment for cancer
- With severe autoimmune disease
Key Trial Info
Start Date :
April 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 4 2022
Estimated Enrollment :
2910 Patients enrolled
Trial Details
Trial ID
NCT04377724
Start Date
April 27 2020
End Date
February 4 2022
Last Update
February 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ETH
Zurich, Switzerland, 8092